Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada:...

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company...

Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in...

Silo Pharma Announces Positive Results from its Topically Administered Formulation of...

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer...

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With...

Load more